Expand KALV Menu
KALV MENU

KALV Latest Press Releases

-- March 25, 2026 --

KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update Business Wire 7:00 AM

-- March 20, 2026 --

KalVista Pharmaceuticals to Present New EKTERLY (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference Business Wire 7:00 AM

-- March 18, 2026 --

KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 Business Wire 7:00 AM

-- March 4, 2026 --

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 7:00 AM

-- March 2, 2026 --

KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY (sebetralstat) Business Wire 7:00 AM

-- February 25, 2026 --

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire 7:00 AM

-- February 18, 2026 --

KalVista Pharmaceuticals Announces Inclusion of EKTERLY (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline Business Wire 7:00 AM

-- February 12, 2026 --

KalVista Pharmaceuticals to Present EKTERLY (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting Business Wire 7:00 AM

-- February 3, 2026 --

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 7:00 AM

-- January 8, 2026 --

KalVista Pharmaceuticals Provides Update on Strong EKTERLY Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results Business Wire 4:05 PM

-- December 22, 2025 --

KalVista Pharmaceuticals Announces Approval of EKTERLY (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema Business Wire 6:00 AM

-- November 10, 2025 --

KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results Business Wire 4:30 PM

-- November 5, 2025 --

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire 7:00 AM

-- November 3, 2025 --

KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025 Business Wire 7:00 AM

-- October 30, 2025 --

KalVista Pharmaceuticals to Present New EKTERLY (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting Business Wire 7:00 AM
Market Data Delayed 15 Minutes